Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma

Abstract: There is an unmet need for effective biological therapies for relapsed central nervous system (CNS) lymphoma. Lenalidomide is active in activated B-cell type diffuse large B-cell lymphoma and rituximab is effective in CNS lymphoma. These observations are the basis for this first trial of a...

Descrición completa

Detalles Bibliográficos

Principais autores:	James L. Rubenstein, Huimin Geng, Eleanor J. Fraser, Paul Formaker, Lingjing Chen, Jigyasa Sharma, Phoebe Killea, Kaylee Choi, Jenny Ventura, John Kurhanewicz, Clifford Lowell, Jimmy Hwang, Patrick Treseler, Penny K. Sneed, Jing Li, Xiaomin Wang, Nianhang Chen, Jon Gangoiti, Pamela N. Munster, Bertil Damato
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2018-07-01
Series:	Blood Advances
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2473952920309502
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!